Personal statin trials for people with side effects and high heart risk
Tests personal statin trials in adults with statin intolerance and high heart risk.
Key facts
- Who runs it
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
- Where
- Amersfoort, Arnhem, Dordrecht, Ede Gld, Nijmegen, Rotterdam, Tilburg, Utrecht, and Zwolle, NetherlandsSee the 11 sites
- Trial code
- Registry title
- Optimizing therapy with n=1-studies: negating the 'nocebo' effect in statin-intolerance
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 249 people, planned
- Started
- 10 Dec 2024
- Expected to end
- 31 Jul 2030
- Type of study
- Interventional
- Record updated
- 27 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with heart disease or familial hypercholesterolemia who stopped statins because of side effects, to test whether an n=1 study helps them take statins again.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Previous cardiovascular disease, or familial hypercholesterolemia (both primary and secondary prevention), with a need for cholesterol-lowering treatment.
- Earlier treatment
- Must have taken two or more statins and stopped them because of (perceived) side effects.
Main reasons for not taking part
- Previous statin use that caused a severe allergic reaction, muscle damage, abnormal liver tests or other severe health problems
- Pregnancy, planned pregnancy within 12 months, or breastfeeding
- History of muscle disease, long-lasting severe pain, severe mental illness, cirrhosis or severe kidney problems
- A cardiovascular event in the past 3 months
- No digital access, or not enough Dutch or English to fill in the questionnaires
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Aged 18 years or older
- Previously taken two or more statins and withdrawn from statins because of (perceived) side effects
- Clinical indication for lipid lowering therapy related to secondary prevention of cardiovascular disease (previous CVD) or prevention of cardiovascular disease (both primary and secondary) in familial hypercholesterolemia
- Provided full informed consent
Who cannot take part
- Clinical judgement of the health care professional that LDL-c lowering therapy cannot be withheld in a patient with a recent cardiovascular event in the past 12 months
- History of myopathy or any other condition that causes severe chronic pain
- History of severe mental illness (as their experience of symptoms may already be altered)
- Clinical judgement of the health care professional that LDLc-lowering therapy is not relevant for the prognosis (e.g. severe frailty, dementia, end-stage heart failure, end-stage malignancy)
- A contra-indication for rosuvastatin therapy related to: a. Previous statin use causing anaphylaxis or other moderate/severe allergic reaction. b. Previous statin use causing myopathy (serum rise of creatine kinase more than 3 times the upper limit of normal) or rhabdomyolysis. c. Previous statin use with liver function abnormalities, defined as aspartate aminotransferase (AST) or alanine aminotransferase >3 times the upper limit of normal. d. Previous statins use causing severe health issues. e. Planned pregnancy within 12 months, pregnancy or breastfeeding. f. Currently taking other drugs with known relevant interactions to rosuvastatin as listed in the Investigational Medicinal Product Dossier (IMPD). g. Any other contraindication for rosuvastatin as listed in the Investigational Medicinal Product Dossier (IMPD)
- History of cirrhosis or severe renal insufficiency (eGFR < 20 ml/min/1,73m2)
- Insufficient ability to fill in questionnaires in the digital platform; a. No access to a smartphone, tablet or personal computer. b. Insufficient understanding of the Dutch or English language
- A recent cardiovascular event in the past 3 months
- Clinical judgement of the health care professional who considers participation unethical or otherwise unwanted
Where in Netherlands
- Meander Medisch CentrumAmersfoort, NetherlandsTaking people
- Rijnstate Ziekenhuis StichtingArnhem, NetherlandsTaking people
- Albert Schweitzer ZiekenhuisDordrecht, NetherlandsTaking people
- Ziekenhuis Gelderse Vallei StichtingEde Gld, NetherlandsTaking people
- Radboud Universitair Medisch Centrum (Radboudumc)Nijmegen, NetherlandsTaking people
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, NetherlandsTaking people
- Maasstad Ziekenhuis StichtingRotterdam, NetherlandsTaking people
- Sint Franciscus Vlietland Groep StichtingRotterdam, NetherlandsTaking people
- Stichting Elisabeth-TweeSteden ZiekenhuisTilburg, NetherlandsTaking people
- Universitair Medisch Centrum UtrechtUtrecht, NetherlandsTaking people
- Isala Klinieken StichtingZwolle, NetherlandsTaking people
About the trial
What the trial wants to find out
The key objective of the study is to assess whether an ‘n=1 study’ (randomized, double blind, cross-over trial with counseling on patients’ individual treatment results) will increase statin use and reduce the prescription of PCSK9i compared to usual care at 12 months (t12m) after randomization.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- N=1-studies In Statin-intolerance; Objectifying Nocebo Effects (NISONE)
- Plain-language title
- Personal statin trials for people with side effects and high heart riskGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 27 August 2026